New combo therapy for metastatic tumors shows early promise but trial halted
NCT ID NCT05491317
First seen Nov 01, 2025 · Last updated May 03, 2026 · Updated 26 times
Summary
This early-stage trial tested a new drug (GEN1042) combined with radiation, with or without another immunotherapy (pembrolizumab), in 13 adults with metastatic solid tumors that had no standard treatment options. The goal was to see if the combination was safe and could shrink tumors, including those not directly treated with radiation. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-CNS TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Leon Berard
Lyon, 69008, France
-
Institut Gustave Roussy
Villejuif, 94805, France
Conditions
Explore the condition pages connected to this study.